These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22816019)

  • 1. ACS chemical neuroscience molecule spotlight on Telcagepant (MK-0974).
    Hopkins CR
    ACS Chem Neurosci; 2011 Jul; 2(7):334-5. PubMed ID: 22816019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there an inherent limit to the efficacy of calcitonin gene-related peptide receptor antagonists in the acute treatment of migraine? A comment.
    Tfelt-Hansen PC
    J Headache Pain; 2009 Dec; 10(6):389-91. PubMed ID: 19779958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.
    Ho TW; Ferrari MD; Dodick DW; Galet V; Kost J; Fan X; Leibensperger H; Froman S; Assaid C; Lines C; Koppen H; Winner PK
    Lancet; 2008 Dec; 372(9656):2115-23. PubMed ID: 19036425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CGRP receptor antagonists: an expanding drug class for acute migraine?
    Negro A; Lionetto L; Simmaco M; Martelletti P
    Expert Opin Investig Drugs; 2012 Jun; 21(6):807-18. PubMed ID: 22512641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine.
    Tepper SJ; Cleves C
    Curr Opin Investig Drugs; 2009 Jul; 10(7):711-20. PubMed ID: 19579177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine.
    Durham PL; Vause CV
    CNS Drugs; 2010 Jul; 24(7):539-48. PubMed ID: 20433208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine.
    Tfelt-Hansen P
    Headache; 2011 Jan; 51(1):118-23. PubMed ID: 21070229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment.
    Tfelt-Hansen P
    J Headache Pain; 2011 Jun; 12(3):275-80. PubMed ID: 21350792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecule of the month. Telcagepant.
    Drug News Perspect; 2009 Mar; 22(2):115. PubMed ID: 19330169
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries.
    Lynch JJ; Regan CP; Edvinsson L; Hargreaves RJ; Kane SA
    J Cardiovasc Pharmacol; 2010 May; 55(5):518-21. PubMed ID: 20164785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there an inherent limit to acute migraine treatment efficacy?
    Bigal ME; Ho TW
    J Headache Pain; 2009 Dec; 10(6):393-4. PubMed ID: 19820895
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis.
    Cui XP; Ye JX; Lin H; Mu JS; Lin M
    Pain Pract; 2015 Feb; 15(2):124-31. PubMed ID: 24382126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examining the binding properties of MK-0974: a CGRP receptor antagonist for the acute treatment of migraine.
    Moore EL; Burgey CS; Paone DV; Shaw AW; Tang YS; Kane SA; Salvatore CA
    Eur J Pharmacol; 2009 Jan; 602(2-3):250-4. PubMed ID: 19084002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine.
    Tepper SJ; Stillman MJ
    Headache; 2008 Sep; 48(8):1259-68. PubMed ID: 18808506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial.
    Connor KM; Aurora SK; Loeys T; Ashina M; Jones C; Giezek H; Massaad R; Williams-Diaz A; Lines C; Ho TW
    Headache; 2011 Jan; 51(1):73-84. PubMed ID: 21070230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tortuous road to an ideal CGRP function blocker for the treatment of migraine.
    Davis CD; Xu C
    Curr Top Med Chem; 2008; 8(16):1468-79. PubMed ID: 18991732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232.
    Hostetler ED; Joshi AD; Sanabria-Bohórquez S; Fan H; Zeng Z; Purcell M; Gantert L; Riffel K; Williams M; O'Malley S; Miller P; Selnick HG; Gallicchio SN; Bell IM; Salvatore CA; Kane SA; Li CC; Hargreaves RJ; de Groot T; Bormans G; Van Hecken A; Derdelinckx I; de Hoon J; Reynders T; Declercq R; De Lepeleire I; Kennedy WP; Blanchard R; Marcantonio EE; Sur C; Cook JJ; Van Laere K; Evelhoch JL
    J Pharmacol Exp Ther; 2013 Nov; 347(2):478-86. PubMed ID: 23975906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Migraine: Telcagepant provides new hope for people with migraine.
    Edvinsson L
    Nat Rev Neurol; 2009 May; 5(5):240-2. PubMed ID: 19488079
    [No Abstract]   [Full Text] [Related]  

  • 19. CGRP-receptor antagonism in migraine treatment.
    Edvinsson L
    Lancet; 2008 Dec; 372(9656):2089-90. PubMed ID: 19036426
    [No Abstract]   [Full Text] [Related]  

  • 20. CGRP antagonists: hope for a new era in acute migraine treatment.
    Schelstraete C; Paemeleire K
    Acta Neurol Belg; 2009 Dec; 109(4):252-61. PubMed ID: 20120204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.